B7-H3 silencing increases paclitaxel sensitivity by abrogating Jak2/Stat3 phosphorylation

Molecular Cancer Therapeutics

Volumn 10, Issue 6, 2011, Pages 960-971

  Liu, Hao ^a,b   Tekle, Christina ^c   Chen, Yih Wen ^a   Kristian, Alexandr ^c   Zhao, Yuhua ^a   Zhou, Ming ^a   Liu, Zixing ^a   Ding, Yan ^a   Wang, Bin ^a   Mælandsmo, Gunhild Mari ^c   Nesland, Jahn Marthin ^d   Fodstad, Oystein ^a,c,e   Tan, Ming ^a  

^a UNIVERSITY OF SOUTH ALABAMA   (United States)

^b SICHUAN UNIVERSITY   (China)

^c UNIVERSITY OF OSLO   (Norway)

^d OSLO UNIVERSITY HOSPITAL   (Norway)

^e RR HF   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

B7 H3 PROTEIN; JANUS KINASE 2; PACLITAXEL; PROTEIN; PROTEIN MCL 1; SHORT HAIRPIN RNA; SMALL INTERFERING RNA; STAT3 PROTEIN; SURVIVIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER GROWTH; CANCER RESISTANCE; CONTROLLED STUDY; DRUG SENSITIVITY; GENE EXPRESSION; GENE OVEREXPRESSION; GENE SILENCING; HUMAN; HUMAN TISSUE; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; TUMOR XENOGRAFT;

ANIMALS; ANTIGENS, CD; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; BREAST NEOPLASMS; CELL LINE; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; JANUS KINASE 2; MICE; MICE, INBRED BALB C; MICE, NUDE; PACLITAXEL; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-BCL-2; RECEPTORS, IMMUNOLOGIC; RNA, SMALL INTERFERING; STAT3 TRANSCRIPTION FACTOR;

EID: 79958746233     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-11-0072     Document Type: Article

References (42)

1. Steinberger P, Majdic O, Derdak SV, Pfistershammer K, Kirchberger S, Klauser C, et al. Molecular characterization of human 4Ig-B7-H3, a member of the B7 family with four Ig-like domains. J Immunol 2004;172:2352-9. (Pubitemid 38182383)
2. Chapoval AI, Ni J, Lau JS, Wilcox RA, Flies DB, Liu D, et al. B7-H3: a costimulatory molecule for T cell activation and IFN-gamma production. Natl Immunol 2001;2:269-74.
3. Leitner J, Klauser C, Pickl WF, Stockl J, Majdic O, Bardet AF, et al. B7-H3 is a potent inhibitor of human T-cell activation: no evidence for B7-H3 and TREML2 interaction. Eur J Immunol 2009;39:1754-64.
4. Suh WK, Gajewska BU, Okada H, Gronski MA, Bertram EM, Dawicki W, et al. The B7 family member B7-H3 preferentially down-regulates T helper type 1-mediated immune responses. Natl Immunol 2003;4:899-906. (Pubitemid 37098661)
5. Zang X, Loke P, Kim J, Murphy K, Waitz R, Allison JP. B7x: a widely expressed B7 family member that inhibits T cell activation. Proc Natl Acad Sci U S A 2003;100:10388-92. (Pubitemid 37071888)
6. Arigami T, Narita N, Mizuno R, Nguyen L, Ye X, Chung A, et al. B7-h3 ligand expression by primary breast cancer and associated with regional nodal metastasis. Ann Surg 2010;252:1044-51.
7. Crispen PL, Sheinin Y, Roth TJ, Lohse CM, Kuntz SM, Frigola X, et al. Tumor cell and tumor vasculature expression of B7-H3 predict survival in clear cell renal cell carcinoma. Clin Cancer Res 2008;14:5150-7.
8. Boorjian SA, Sheinin Y, Crispen PL, Farmer SA, Lohse CM, Kuntz SM, et al. T-cell coregulatory molecule expression in urothelial cell carcinoma: clinicopathologic correlations and association with survival. Clin Cancer Res 2008;14:4800-8.
9. Zang X, Thompson RH, Al-Ahmadie HA, Serio AM, Reuter VE, Eastham JA, et al. B7-H3 and B7x are highly expressed in human prostate cancer and associated with disease spread and poor outcome. Proc Natl Acad Sci U S A 2007;104:19458-63.
10. Sun Y, Wang Y, Zhao J, Gu M, Giscombe R, Lefvert AK, et al. B7-H3 and B7-H4 expression in non-small-cell lung cancerLung Cancer 2006;53:143-51.
11. Yamato I, Sho M, Nomi T, Akahori T, Shimada K, Hotta K, et al. Clinical importance of B7-H3 expression in human pancreatic cancer. Br J Cancer 2009;101:1709-16.
12. Chen YW, Tekle C, Fodstad O. The immunoregulatory protein human B7H3 is a tumor-associated antigen that regulates tumor cell migration and invasion. Curr Cancer Drug Targets 2008;8:404-13.
13. Elenbaas B, Spirio L, Koerner F, Fleming MD, Zimonjic DB, Donaher JL, et al. Human breast cancer cells generated by oncogenic transformation of primary mammary epithelial cells. Genes Dev 2001;15:50-65. (Pubitemid 32060682)
14. Tan M, Yu D. Molecular mechanisms of erbB2-mediated breast cancer chemoresistance. Adv Exp Med Bio 2007;608:119-29.
15. Barre B, Vigneron A, Perkins N, Roninson IB, Gamelin E, Coqueret O. The STAT3 oncogene as a predictive marker of drug resistance. Trends Mol Med 2007;13:4-11. (Pubitemid 46027724)
16. Al Zaid, Siddiquee K, Turkson J. STAT3 as a target for inducing apoptosis in solid and hematological tumors. Cell Res 2008;18:254-67. (Pubitemid 351206162)
17. Burke WM, Jin X, Lin HJ, Huang M, Liu R, Reynolds RK, et al. Inhibition of constitutively active Stat3 suppresses growth of human ovarian and breast cancer cells. Oncogene 2001;20:7925-34. (Pubitemid 34002969)
18. Levy DE, Darnell JE Jr. Stats: transcriptional control and biological impact. Natl Rev Mol Cell Biol 2002;3:651-62. (Pubitemid 34987786)
19. Levy DE, Inghirami G. STAT3: a multifaceted oncogene. Proc Natl Acad Sci U S A 2006;103:10151-2. (Pubitemid 44051135)
20. Schlessinger K, Levy DE. Malignant transformation but not normal cell growth depends on signal transducer and activator of transcription 3. Cancer Res 2005;65:5828-34. (Pubitemid 40911187)
21. Gariboldi MB, Ravizza R, Molteni R, Osella D, Gabano E, Monti E. Inhibition of Stat3 increases doxorubicin sensitivity in a human metastatic breast cancer cell line. Cancer Lett 2007;258:181-8. (Pubitemid 350101017)
22. Gritsko T, Williams A, Turkson J, Kaneko S, Bowman T, Huang M, et al. Persistent activation of stat3 signaling induces survivin gene expression and confers resistance to apoptosis in human breast cancer cells. Clin Cancer Res 2006;12:11-9. (Pubitemid 43166170)
23. Aoki Y, Feldman GM, Tosato G. Inhibition of STAT3 signaling induces apoptosis and decreases survivin expression in primary effusion lymphoma. Blood 2003;101:1535-42. (Pubitemid 36182531)
24. Catlett-Falcone R, Landowski TH, Oshiro MM, Turkson J, Levitzki A, Savino R, et al. Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity 1999;10:105-15. (Pubitemid 29077388)
25. Epling-Burnette PK, Liu JH, Catlett-Falcone R, Turkson J, Oshiro M, Kothapalli R, et al. Inhibition of STAT3 signaling leads to apoptosis of leukemic large granular lymphocytes and decreased Mcl-1 expression. J Clin Invest 2001;107:351-62.
26. Grandis JR, Drenning SD, Chakraborty A, Zhou MY, Zeng Q, Pitt AS, et al. Requirement of Stat3 but not Stat1 activation for epidermal growth factor receptor-mediated cell growth In vitro. J Clin Invest 1998;102:1385-92. (Pubitemid 28467567)
27. Grandis JR, Drenning SD, Zeng Q, Watkins SC, Melhem MF, Endo S, et al. Constitutive activation of Stat3 signaling abrogates apoptosis in squamous cell carcinogenesis in vivo. Proc Natl Acad Sci U S A 2000;97:4227-32. (Pubitemid 30226115)
28. Mora LB, Buettner R, Seigne J, Diaz J, Ahmad N, Garcia R, et al. Constitutive activation of Stat3 in human prostate tumors and cell lines: direct inhibition of Stat3 signaling induces apoptosis of prostate cancer cells. Cancer Res 2002;62:6659-66. (Pubitemid 35364135)
29. Niu G, Bowman T, Huang M, Shivers S, Reintgen D, Daud A, et al. Roles of activated Src and Stat3 signaling in melanoma tumor cell growth. Oncogene2002;21:7001-10.
30. Song L, Turkson J, Karras JG, Jove R, Haura EB. Activation of Stat3 by receptor tyrosine kinases and cytokines regulates survival in human non-small cell carcinoma cells. Oncogene 2003;22:4150-65. (Pubitemid 36876236)
31. Henderson IC, Berry DA, Demetri GD, Cirrincione CT, Goldstein LJ, Martino S, et al. Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 2003;21:976-83. (Pubitemid 46594124)
32. Hsieh FC, Cheng G, Lin J. Evaluation of potential Stat3-regulated genes in human breast cancer. Biochem Biophys Res Commun 2005;335:292-9. (Pubitemid 41140220)
33. Jing N, Tweardy DJ. Targeting Stat3 in cancer therapy. Anticancer Drugs 2005;16:601-7. (Pubitemid 40863092)
34. Andersson Y, Juell S, Fodstad O. Downregulation of the antiapoptotic MCL-1 protein and apoptosis in MA-11 breast cancer cells induced by an anti-epidermal growth factor receptor-pseudomonas exotoxin a immunotoxin. Int J Cancer 2004;112:475-83. (Pubitemid 39390614)
35. Chetoui N, Sylla K, Gagnon-Houde JV, Alcaide-Loridan C, Charron D, Al-Daccak R, et al. Down-regulation of mcl-1 by small interfering RNA sensitizes resistant melanoma cells to fas-mediated apoptosis. Mol Cancer Res 2008;6:42-52. (Pubitemid 351378165)
36. Wei SH, Dong K, Lin F, Wang X, Li B, Shen JJ, et al. Inducing apoptosis and enhancing chemosensitivity to gemcitabine via RNA interference targeting Mcl-1 gene in pancreatic carcinoma cell. Cancer Chemother Pharmacol 2008;62:1055-64.
37. Lu J, Tan M, Huang WC, Li P, Guo H, Tseng LM, et al. Mitotic deregulation by survivin in ErbB2-overexpressing breast cancer cells contributes to Taxol resistance. Clin Cancer Res 2009;15:1326-34.
38. Arriola E, Moreno A, Varela M, Serra JM, Falo C, Benito E, et al. Predictive value of HER-2 and topoisomerase IIalpha in response to primary doxorubicin in breast cancer. Eur J Cancer 2006;42:2954-60. (Pubitemid 44667470)
39. Dougherty MK, Schumaker LM, Jordan VC, Welshons WV, Curran EM, Ellis MJ, et al. Estrogen receptor expression and sensitivity to paclitaxel in breast cancer. Cancer Biol Ther 2004;3:460-7. (Pubitemid 41350861)
40. Ross DT, Scherf U, Eisen MB, Perou CM, Rees C, Spellman P, et al. Systematic variation in gene expression patterns in human cancer cell lines. Nat Genet 2000;24:227-35. (Pubitemid 30132189)
41. Sellappan S, Grijalva R, Zhou X, Yang W, Eli MB, Mills GB, et al. Lineage infidelity of MDA-MB-435 cells: expression of melanocyte proteins in a breast cancer cell line. Cancer Res 2004;64:3479-85. (Pubitemid 38657921)
42. Chambers AF. MDA-MB-435 and M14 cell lines: identical but not M14 melanoma? Cancer Res 2009;69:5292-3.